Engert: Hematologic Malignancies: Hodgkin Lymphoma: A Comprehensive Update on Diagnostics and Clinics

Hodgkin lymphoma is one of the best curable malignancies both in adult and pediatric oncology. Today, more than 80% of all patients can be cured with risk-adapted treatment including chemotherapy and radiotherapy. This progress is largely due to the development of multiagent chemotherapy more than 40 years ago and the improvements in radiotherapy. Since then, this fascinating disease has been in the focus of scientific and clinical research. Major more recent achievements were the definite proof that Hodgkin lymphoma is a true malignancy despite its peculiar histology with the Hodgkin and Reed-Sternberg cells derived from “crippled” B-lymphocytes.
Establishing immortal cell lines from patients with end-stage disease initiated a variety of different research activities into the pathophysiology, immunology, and treatment. The discovery of the Ki-1 antigen that was expressed in high density on H-RS cells substantially improved the prognostic precision since nearly all malignant cells in Hodgkin lymphoma tissue are strongly expressing this antigen, which was later designated to the CD30 cluster. Monoclonal antibodies against this antigen were not only being successfully used for immunophenotyping but also exploited therapeutically. After a number of nonsuccessful clinical trials with antibody constructs or fully human monoclonal antibodies targeting CD30, this story now seems to come full circle with the advent of an anti-CD30 antibody-drug conjugate that has given remarkable responses in end-stage Hodgkin lymphoma patients.
Due to the substantially improved prognosis and the generally young age of patients affected, Hodgkin lymphoma has also become a model to study long-term effects of successful radiotherapy and chemotherapy. Today, more patients die from treatment-related long-term toxicity than from uncontrolled Hodgkin lymphoma. We must thus very carefully balance our attempts to further improve disease control with the need to keep the risk of long-term consequences as low as possible. In addition, there are also a number of relevant physical and psychosocial issues that need to be further exploited including the risk of infertility, and fatigue. Fortunately, after more than 20 years of standstill, we now experience the development of new-targeted treatment also for patients with Hodgkin lymphoma. This hopefully might result in more individualized and less toxic treatments for our patients.
This book should give you an overview on past and current achievements in the area of Hodgkin lymphoma with a special emphasis on late effects and new treatment options. 

About the Author
Andreas Engert M.D. is Professor for Internal Medicine, Hematology and Oncology. He received his medical degree at the University of Hannover and had his medical training at the University of Hannover and the University Hospital of Cologne. Between 1988 and 1990 he worked at the Imperial Cancer Research Fund in London on new immunotherapeutic approaches for cancer. After returning to Cologne, he and his group focused on developing antibody-based immunotherapy for patients with malignant lymphoma resulting in a number of experimental phase I/II clinical trials. He finished his postdoctoral lecture qualification in 1995, was appointed consultant and became head of staff 1996. He was appointed coordinating editor of the Cochrane Hematological Malignancies Group (CHMG) and vice director of the Department for Hematology and Oncology in 2000. After Serving as Secretary of the German Hodgkin Study Group (GHSG) since 1999, Prof. Engert was elected GHSG chairman in 2007. For his scientific work, he has received numerous awards including the Ludwig-Heilmeyer-Medal, the Arthur-Pappenheim Award and the Research Award of the University of Cologne. The focus of his research for many years has been the development of targeted therapy to combat malignancy. Activities include constructs such as bispecific monoclonal antibodies, radioimmunoconjugates, humanized antibodies or immunoligands for diseases such as neuroblastoma, chronic lymphocytic, acute leukemias and malignant lymphoma. Prof. Engert treats patients with all malignancies and consults for lymphoma patients. In addition he is active in the field of evidence-based medicine as editor of the Cochrane Review Group for Hematological Malignancies (CHMG). The clinical focus of his work is the German Hodgkin Study Group (GHSG) with all of its different facets including planning and conducting clinical trials of all phases. The GHSG has conducted more than 20 randomized studies with more than 20.000 patients overall registered and is actively involved in a number of early clinical trials evaluating new drugs for patients with Hodgkin Lymphoma. 

Part I From Hodgkin’s Disease to Hodgkin Lymphoma
  • 1 Epidemiology
  • 2 The Role of Viruses in the Genesis of Hodgkin Lymphoma
  • 3 Pathology and Molecular Pathology of Hodgkin Lymphoma
  • 4 Microenvironment, Cross-Talk, and Immune Escape Mechanisms
Part II Diagnosis and Treatment
  • 5 Clinical Evaluation
  • 6 Functional Imaging
  • 7 Prognostic Factors
  • 8 Principles of Radiation Techniques in Hodgkin Lymphoma
  • 9 Principles of Chemotherapy in Hodgkin Lymphoma
  • 10 Treatment of Early Favorable Hodgkin Lymphoma
  • 11 Treatment of Early Unfavorable HL
  • 12 Treatment of Advanced Stage Hodgkin Lymphoma
  • 13 Relapsed and Refractory Hodgkin Lymphoma
  • 14 Pediatric Hodgkin Lymphoma
Part III Special Clinical Situations
  • 15 Lymphocyte-Predominant Hodgkin Lymphoma
  • 16 The Management of Hodgkin Lymphoma During Pregnancy
  • 17 The Management of HIV-Hodgkin Lymphoma
  • 18 The Management of Elderly Patients with Hodgkin Lymphoma
  • 19 Allogeneic Transplantation for Relapsed Hodgkin Lymphoma
  • 20 New Agents for Patients with Hodgkin Lymphoma
Part IV Survivorship
  • 21 Quality of Life in Hodgkin Lymphoma
  • 22 Second Malignancy Risk After Treatment of Hodgkin Lymphoma
  • 23 Cardiovascular and Pulmonary Late Effects
  • 24 Gonadal Dysfunction and Fertility Preservation in Hodgkin Lymphoma Patients
Part V Future Prospects
  • 25 What Will We Learn from Genomics and Proteomics in Hodgkin Lymphoma?
  • 26 Personalized Medicine in Hodgkin Lymphoma?

Product Details
  • Hardcover: 390 pages
  • Publisher: Springer; 1st edition (November 1, 2010)
  • Language: English
  • ISBN-10: 3642127797
  • ISBN-13: 978-3642127793
List Price: $219.00

Medical Lecture Note Copyright © 2011